Core Viewpoint - The article highlights the successful IPO of Heng Rui Medicine on the Hong Kong Stock Exchange, marking it as the largest pharmaceutical IPO of the year, with a market capitalization exceeding 390 billion HKD and a notable increase in share price upon opening [3][4]. Company Overview - Heng Rui Medicine's IPO was priced at 44.05 HKD per share, and it saw a nearly 30% surge on its opening day, establishing a market value of over 390 billion HKD [3]. - The cornerstone investors for this IPO included prominent entities such as the Government of Singapore Investment Corporation (GIC), Invesco, UBS Global Asset Management, Hillhouse Capital, and Boyu Capital, with total subscriptions exceeding 4.1 billion HKD [3]. Leadership and History - The article discusses the founder, Sun Piaoyang, who is recognized as a pivotal figure in the company’s success, transforming a small pharmaceutical factory into a major player in the Chinese pharmaceutical industry [5][8]. - Sun Piaoyang's journey began in 1982 when he graduated from China Pharmaceutical University and started working at the Lianyungang Pharmaceutical Factory, which later became Heng Rui Medicine [5][7]. Financial Performance - For the first three quarters of 2024, Heng Rui Medicine reported revenues of 20.19 billion CNY and a net profit of 4.62 billion CNY, with net profit reaching a historical high [10]. - The sales revenue from innovative drugs accounted for 47.7% of the company's total revenue, indicating a significant contribution from generic drugs [10][11]. Innovation and R&D - Heng Rui Medicine focuses on developing innovative drugs in areas such as oncology, metabolism, cardiovascular diseases, immunology, respiratory diseases, and neuroscience, with 17 innovative drugs already on the market and over 90 candidates in the pipeline [11]. - The company has emphasized a dual strategy of "self-research + acquisition" to enhance its product offerings and navigate market challenges [8][12]. Strategic Goals - The IPO aims to enhance Heng Rui Medicine's global presence and optimize its capital structure, facilitating international collaborations and expanding its production and R&D facilities both domestically and abroad [12]. - The article notes that the Hong Kong market serves as a crucial platform for the company to increase its international visibility and attract a broader investor base [12]. Market Context - The article places Heng Rui Medicine's IPO within the broader context of a booming Hong Kong stock market, which has seen a surge in new listings and capital raising activities, with over 150 listing applications currently under review [15][17]. - The successful IPOs of other companies, such as Ningde Times and Mixue Ice City, illustrate a vibrant market environment, with significant capital inflows and investor interest [15][16].

Core Viewpoint - Heng Rui Medicine has successfully listed on the Hong Kong Stock Exchange, achieving a market capitalization exceeding HKD 390 billion, marking the largest pharmaceutical IPO of the year [1][9]. Company Overview - Heng Rui Medicine's IPO price was set at HKD 44.05, with the stock opening nearly 30% higher on its debut [1]. - The company was founded by Sun Piaoyang, who has been instrumental in its growth from a small pharmaceutical factory to a leading player in the Chinese pharmaceutical industry [2][4]. - The company has a strong financial position, with cash and cash equivalents amounting to approximately CNY 21.4 billion and no bank loans [8]. Financial Performance - For the first three quarters of 2024, Heng Rui Medicine reported revenues of CNY 20.19 billion and a net profit of CNY 4.62 billion, with net profit reaching a historical high [8]. - The sales revenue from innovative drugs accounted for 47.7% of total revenue, indicating a significant contribution from generic drugs [8]. - The proportion of innovative drug sales increased from 38.1% in 2022 to 43.4% in 2023 [8]. Strategic Intentions - The IPO is part of Heng Rui Medicine's strategy to expand internationally and enhance its global presence, with plans to use the proceeds for new production and R&D facilities both in China and overseas [9]. - The company aims to optimize its capital structure and diversify its financing channels through the H-share issuance [9]. Market Context - The Hong Kong Stock Exchange has seen a surge in IPO activity, with around 150 applications currently under review, including several leading enterprises [1][14]. - The overall fundraising in the Hong Kong market has exceeded HKD 60 billion this year, significantly higher than the previous year [14].

Core Viewpoint - The recent IPOs in the Hong Kong stock market have shown strong profitability, with significant price increases for newly listed stocks like 恒瑞医药 (Hengrui Medicine) and MIRXES-B during the dark pool trading period [1][2]. Company Summaries 恒瑞医药 (Hengrui Medicine) - 恒瑞医药, an established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D expenditure of 29.4% of total revenue in 2024 [6]. - The company has returned approximately RMB 80.29 billion in cash dividends to shareholders since its A-share listing, which is 16.8 times the capital raised at that time [6]. - 恒瑞医药 has 19 marketed innovative drugs and over 90 new molecular entities in clinical or later stages of development [6]. - The total revenue for 恒瑞医药 is projected to be RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of about 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of approximately 4% [6]. - The revenue contribution from innovative drugs increased from 38.1% in 2022 to 43.4% in 2023, and is expected to reach 46.3% in 2024, while the contribution from generic drugs decreased from 60.3% in 2022 to 42.0% in 2024 [7]. MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in microRNA technology for disease screening and diagnostics, particularly in cancer detection [7]. - The company is one of the few globally to have received regulatory approval for molecular cancer screening IVD products, and is the first to receive such approval for molecular gastric cancer screening [7]. - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [7]. - The subscription multiple for MIRXES-B is significantly lower than that of 恒瑞医药, with 25 times compared to 恒瑞医药's 409 times [7]. Market Trends - The recent trend in the Hong Kong IPO market shows a strong upward movement, with only 6 out of 23 newly listed companies this year experiencing a decline on their first trading day, while others have seen substantial gains [8].

Core Viewpoint - The article highlights the significant price increases of two new stocks, 恒瑞医药 (Hengrui Medicine) and MIRXES-B, during the dark trading period before their listing on the Hong Kong stock market, indicating strong market interest and potential investment opportunities. Group 1: Hengrui Medicine - Hengrui Medicine, a well-established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D investment of 29.4% of total revenue in 2024 [3] - The company has a diverse portfolio with 19 marketed innovative drugs and over 90 in clinical or later stages of development [4] - Hengrui's total revenue is expected to reach RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of approximately 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of about 4% [4] - The sales revenue from innovative drugs has increased from 38.1% of total revenue in 2022 to 43.4% in 2023, and is projected to reach 46.3% in 2024, while sales from generic drugs are decreasing [4] Group 2: MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in miRNA technology for disease screening and diagnostics, particularly in cancer detection [4] - The company is one of the few globally to have received regulatory approval for its molecular cancer screening IVD products, including the first approval for molecular gastric cancer screening [4] - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [5] - The subscription ratio for MIRXES-B is significantly lower than that of Hengrui Medicine, with 25 times compared to Hengrui's 409 times [6]

Core Viewpoint - The article discusses the upcoming IPO of FWD Group, led by Richard Li, the son of Li Ka-shing, highlighting its growth and expansion in the insurance sector across Asia-Pacific, particularly its significant customer base from mainland China [3][4][6]. Group 1: Company Overview - FWD Group has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, with Richard Li as its leader, who has established the company through strategic acquisitions since 2013 [3][5]. - The company has approximately 60,000 policyholders from mainland China, indicating a strong market presence [4][6]. - FWD Group's business model focuses on customer-centric and digital empowerment strategies, leading to rapid growth in the insurance market [5][6]. Group 2: Financial Performance - From 2014 to 2024, FWD Group's annualized new premiums are projected to grow 5.2 times, from $309 million to $1.916 billion [6]. - The company reported net insurance and investment performance of $493 million, $470 million, and $911 million for the years 2022 to 2024, respectively, with a turnaround to profitability expected in 2024 [7]. - The annualized new premium from mainland Chinese visitors has seen a growth of 6.3 times from 2022 to 2024, showcasing the potential for further expansion in this market [7]. Group 3: Market Context - The Hong Kong IPO market is experiencing a resurgence, with significant listings such as CATL and Heng Rui Pharmaceutical, indicating a robust environment for new public offerings [13][14]. - The total fundraising amount from new IPOs in Hong Kong has exceeded HKD 60 billion, marking a more than sixfold increase compared to the previous year [13][15]. - The sentiment among investors has shifted positively, with a growing interest in Hong Kong listings, contrasting with previous perceptions of low liquidity and valuation issues [15].

在深度共话环节，中信建投投资银行委员会执行总经理赵旭、松禾资本合伙人赵亮、启赋资本合伙人唐华林、华商律师事务所合伙人徐舜芝、毕马威中国审 计合伙人徐司辞围绕"港股IPO最新动向带给企业及投资机构的机遇及挑战"开展热烈讨论。从上市中介机构视角出发，嘉宾们就审计实操、募集资金管理、 港股再融资等内容分享见解，并深入探讨港股上市备案规范性要求、港股与A股财务会计处理差异等企业关注的焦点问题。 记者了解到，近年来，赴港上市热度持续攀升。2024年4月，中国证监会发布《五项资本市场对港合作措施》，明确支持内地行业龙头企业赴港上市；同年 10月，香港证监会和港交所联合声明，针对符合资格的A股公司推出快速审批时间表。5月7日，中国证监会主席吴清表示，将创造条件支持优质中概股企业 回归内地和香港股市。如今，香港已成为A股公司境外融资上市及中概股回流上市的首选平台。未来，深证企服中心将持续发挥平台纽带作用，整合深港两 地资源，为更多优质企业提供上市辅导、融资对接等全周期服务，搭建深港金融合作桥梁，助力企业借助资本市场实现跨越式发展。 （本文图片由前海管理局提供） 深圳商报·读创客户端记者 范宏韬 5月16日，在深圳市委金融办、 ...

上证报中国证券网讯（记者 徐潇潇）日前，深圳证监局、深圳市委金融办等多个部门开展了星耀鹏城"益企上市深证同行"赴港上市培训会。根据港交所环 球上市服务部副总裁陆琛健介绍，港交所随着市场变化动态创新上市机制，从8A章节、18A章节、18C章节到最新开设的"科企专线"，为港股市场发展不断 注入新动能。 中信建投证券投资银行委员会执行总经理赵旭表示，香港资本市场具备更便捷的再融资通道、更宽松的募集资金监管环境、更丰富的全球并 购手段、更多元的人才激励方式。 晶泰控股是港股18C规则下发行第一股的公司，其投融资副总裁何飞宏分享了相关经验："18C章节适应于新一代信息技 术、先进硬件及软件、先进材料、新能源及节能环保、新食品及农业技术等行业及领域。18C制度将对全国资本市场和特专科技产业发挥积极作用。"他表 示，"港股IPO应充分考虑发行窗口的选择、公司长期发展的愿景和逻辑、投资者结构等多维度因素。" 谈及中概股回流香港流程及架构，华商律师事务所高 级合伙人徐舜芝称，中概股回流香港以双重主要上市以及二次上市为主。在备案新规指导下，境内企业境外上市应关注备案主体、备案时限、安全审查、保 密要求、出资情况等方面。 近期，港 ...

下午，赴港上市培训活动正式举办。宝安区企业服务中心杨海栋主任致辞介绍，宝安区精准服务企业， 常态化开展上市培育活动，构建诉求多层级快速协调处理机制，全力扫清企业上市障碍；同时，通过建 立上市培育库、优化企业培育体系，全方位助力企业发展壮大。 活动现场，港交所上市服务部副总裁陆琛健对港交所市场动态及上市政策进行深入解读。中信建投证券 投资银行委员会执行总经理赵旭带来A股上市公司香港上市的专题分享。港交所上市企业晶泰控股融资 副总裁何飞宏则分享了港股18C规则相关的宝贵经验。 活动现场。主办方供图 人民网深圳5月19日电 (刘森君)5月16日，深圳市深证中小企业服务中心(以下简称"深证企服")联合深圳 前海股权交易中心等服务机构，在前海举办"星耀鹏城"赴港上市培训会。百余家意向赴港上市的深圳企 业代表、私募基金管理人参与活动。 当日上午，深证企服率先召开赴港上市闭门交流会。7家深圳市上市后备企业高管与会交流，港交所专 家针对企业代表的提问一一解答，并建立起后续持续对接与沟通的渠道。 深度共话环节，来自投资机构、律所等的多位嘉宾，围绕"港股IPO最新动向带给企业及投资机构的机 遇及挑战"主题，进行了热烈讨论。 深证 ...

Group 1 - The core point of the article is that CATL is set to launch the largest IPO in Hong Kong in nearly three years, with plans to raise approximately 307.18 billion HKD (around 290 billion RMB) by issuing 117.9 million H-shares at a maximum price of 263 HKD per share [1] - CATL's IPO will only dilute existing shareholders' equity slightly, with the new shares representing just 2.61% of the expanded share capital [1][2] - The IPO has attracted significant interest from cornerstone investors, with 65.7% of the shares being subscribed by 23 cornerstone investors, including major foreign and domestic institutions [2] Group 2 - Retail investors have shown strong enthusiasm, with total subscription amounts exceeding 1.4 trillion HKD (approximately 1.292 trillion RMB), indicating high demand for CATL's shares [2] - CATL plans to allocate 90% of the funds raised from the IPO to the construction of its energy storage projects in Hungary, with a total planned investment of approximately 7 billion euros (around 56 billion RMB) [3] - The European market presents a unique opportunity for CATL, as there are currently no strong local battery manufacturers, positioning CATL as a key player in the region [4] Group 3 - The successful IPO of CATL may create challenges for other battery manufacturers in Hong Kong, as the increased market attractiveness of CATL could make it more difficult for smaller firms to secure financing [5]

Core Viewpoint - Cambridge Technology is facing scrutiny over its upcoming Hong Kong IPO due to concerns about the timing of its fundraising in relation to significant share reductions by major shareholders and inconsistencies in its financial data [1][11][12]. Financial Performance - Cambridge Technology reported fluctuating revenues and net profits from 2022 to 2024, with revenues of RMB 3.786 billion, RMB 3.087 billion, and RMB 3.652 billion, reflecting year-on-year growth rates of 29.66%, -18.46%, and 18.31% respectively [2][3]. - The net profits for the same period were RMB 171 million, RMB 95 million, and RMB 167 million, with year-on-year growth rates of 154.93%, -44.59%, and 75.42% respectively [2][3]. IPO Fundraising Purpose - The company plans to use the proceeds from the Hong Kong IPO to enhance production capacity for optical modules, broadband, and wireless solutions, as well as to improve R&D capabilities and supplement working capital [2][6]. - The specific amount to be raised has not yet been disclosed [2]. Previous Fundraising Issues - Cambridge Technology's previous fundraising projects have faced delays and changes, with the most significant project, the optical module project, experiencing multiple extensions and currently being integrated into a new project [3][4][5]. - The optical module project was initially set to be completed in one year but has now been extended to five years without generating expected benefits [4][5]. Supplier Data Discrepancies - There are notable discrepancies between the procurement data reported in the company's annual report and the Hong Kong IPO prospectus, raising questions about the reliability of the financial data [8][9]. - For instance, the procurement amounts for the top five suppliers differ significantly between the two documents, with the annual report showing lower totals compared to the IPO prospectus [8][9]. Shareholder Actions - The controlling shareholders plan to reduce their holdings by up to 3% through block trades and open market transactions, which has raised investor concerns about the timing of the IPO and the potential implications for company governance [11][12][13]. - The company has stated that the reduction in shareholding is based on the shareholders' business needs and is not directly related to the IPO [12][13].